Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteremia

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the leading causes of community-onset and nosocomial bacteremia worldwide and is associated with significant morbidity and mortality [1-3]. Nearly 65,000 cases of MRSA bacteremia (MRSA-B) are reported annually in the United States alone with mortality rates often in excess of 25% [4,5]. While vancomycin remains a mainstay of treatment for MRSA-B [6], concern has been raised regarding suboptimal outcomes for patients in whom the pharmacodynamic target of therapy is not achieved [7,8].

Source: International Journal of Antimicrobial Agents - August 31, 2018 Category: Drugs & Pharmacology Authors: Bryan T. Mogle, Jeffrey M. Steele, Robert W. Seabury, Utkarsh J. Dang, Wesley D. Kufel Source Type: research